Brookline Capital Management Comments on Procaps Group S.A.’s Q4 2022 Earnings (NASDAQ:PROC)

Procaps Group S.A. (NASDAQ:PROCGet Rating) – Investment analysts at Brookline Capital Management lowered their Q4 2022 earnings per share (EPS) estimates for shares of Procaps Group in a research report issued to clients and investors on Wednesday, November 16th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of $0.08 for the quarter, down from their previous estimate of $0.27. The consensus estimate for Procaps Group’s current full-year earnings is $0.12 per share.

Procaps Group (NASDAQ:PROCGet Rating) last released its quarterly earnings data on Tuesday, August 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.20). Procaps Group had a net margin of 13.82% and a negative return on equity of 243.60%. The company had revenue of $112.42 million for the quarter, compared to analyst estimates of $123.90 million.

Procaps Group Price Performance

PROC opened at $6.87 on Monday. Procaps Group has a one year low of $5.86 and a one year high of $10.50. The stock’s fifty day moving average is $6.90 and its 200-day moving average is $7.73.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PROC. Citadel Advisors LLC bought a new stake in shares of Procaps Group during the 2nd quarter worth about $263,000. Millennium Management LLC raised its holdings in Procaps Group by 15.9% in the 2nd quarter. Millennium Management LLC now owns 101,430 shares of the company’s stock valued at $945,000 after acquiring an additional 13,908 shares in the last quarter. Finally, State Street Corp acquired a new position in Procaps Group in the 3rd quarter valued at approximately $89,000. 1.48% of the stock is owned by institutional investors and hedge funds.

About Procaps Group

(Get Rating)

Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.

Recommended Stories

Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.